Hartmut Kirchner - Concepedia

Author

Hartmut Kirchner

Also Known As

A Khachatur Yan, Carvajal- Carmona Lg, H H Kirchner, H Kirchner, H Wiesneth, H. H. Kirchner, H. Hartmut Kirchner, H. Kirchner, H.H. Kirchner, HARTMUT KIRCHNER

181

Publications

8.5K

Citations

H-Index

Concepts

All Affiliations

Medizinische Hochschule Hannover Universität Hamburg Goethe University Frankfurt Christian-Albrechts-Universität zu Kiel Centrum für Integrierte Onkologie

About

Hartmut Kirchner is an author at Medizinische Hochschule Hannover specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	47	4K
2	Cell Biology	9	9	384
3	Health Sciences	4	4	162
4	Allergy	1	1	15
5	Cellular Physiology	1	1	11

Hartmut Kirchner

Publications

Citations

H-Index

Page 1

	Year	Citations
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial Norbert Schmitz, Beate Pfistner, M. Sextro, The Lancet Cell TherapyTransplantationMarrow TransplantationMedicineRandomised Trial	2002	1.1K
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma Andreas Engert, Annette Plütschow, Hans Theodor Eich, New England Journal of Medicine	2010	907
Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells Ulrich Schwab, Harald Stein, Johannes Gerdes, Nature Lymphoid NeoplasiaLaboratory ImmunologyImmunodeficienciesImmunologyImmune Regulation	1982	873
Incidence and Prognostic Influence of <i>DNMT3A</i> Mutations in Acute Myeloid Leukemia Felicitas Thol, Frédérik Damm, Andrea Lüdeking, Journal of Clinical Oncology	2011	375
Impact of <i>IDH1</i> R132 Mutations and an <i>IDH1</i> Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor Katharina Wagner, Frédérik Damm, Gudrun Göhring, Journal of Clinical Oncology	2010	240
Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) Jens Atzpodien, Hartmut Kirchner, Udo Jonas, Journal of Clinical Oncology	2004	224
Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease Andreas Josting, Christian Rudolph, Marcel Reiser, Annals of Oncology Refractory Hodgkin ’Lymphoid NeoplasiaLow ToxicityClinical TherapeuticMedicine	2002	219
Interleukin-2 Based Home Therapy of Metastatic Renal Cell Carcinoma: Risks and Benefits in 215 Consecutive Single Institution Patients Enrique Lopez Hänninen, Hartmut Kirchner, Jens Atzpodien The Journal of Urology	1996	194
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia Felicitas Thol, Frédérik Damm, Katharina Wagner, Blood	2010	183
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia Rüdiger Hehlmann, Ute Berger, Markus Pfirrmann, Blood	2007	168

Page 1